Cervical spondylitic myeloradiculopathy due to chronic brucellosis in a Ugandan teenager

*Kyebambe P1, Kasyaba R1, Nkakyekorera S2

1. Internal Medicine department, Kabale Regional Referral Hospital
2. Radiology department, Kabale Regional Referral Hospital

Keywords: Cervical spondylitis brucellosis myeloradiculopathy

Introduction

Brucellosis is a worldwide zoonosis that causes much clinical morbidity as well as considerable loss of productivity in animal husbandry. It has been present for millennia and has managed to elude eradication even in most developed countries1. Transmission of brucellosis to humans occurs through the consumption of infected, un-pasteurized animal products, through ruptures in skin/mucous membranes in direct contact with infected animal parts and fluids (e.g. placenta, urine, dung) and via inhalation of infected aerosolized particles.

Brucellosis is an occupational disease in herdsmen, abattoir/dairy workers, veterinarians, and microbiologic laboratory personnel. Consumption of unpasteurized dairy products e.g. raw milk, yoghurt, and ice cream is the commonest means of transmission. Infection is also acquired through consumption of undercooked/under-roasted meats1. Human-to-human transmission through sexual fluids and breast milk has been documented2,3.

Six species of brucella are known to cause human disease namely: B. melitensis (from goats, sheep, camels), B. abortus (from cows), B. suis (from pigs), B. canis (from dogs) and the recently discovered marine types: Brucella pinnipediae (from dolphins and whales) and B. cetaceae (from seals). The vast majority of cases worldwide are attributed to B. melitensis1. After entering the human body and being taken up by local tissue lymphocytes, brucellae are transferred through regional lymph nodes into the circulation and are subsequently seeded throughout the body, with tropism for the reticuloendothelial system. The incubation period usually ranges from 2 to 4 weeks1. The disease is protean and complications can occur in any organ or body system namely: genitourinary, haematological, cutaneous and ocular1,4,5,6.

Brucellosis in Africa

Human brucellosis has been documented in Uganda and Africa for decades, however, the disease had never been considered to be a big public health problem, probably due to under-diagnosis5. Recently, there have been increased reports of this zoonosis on the African continent6-13.

Objectives of reporting the case

1. To raise awareness that brucellosis and its complications do exist in Africa.
2. To demonstrate that neurobrucellosis can resemble non-communicable diseases like Amyotrophic Lateral Sclerosis (ALS).
3. To share with readers one of our most spectacular clinical experiences and demonstrate to them that a diagnosis and cure of complicated brucellosis is possible even in centres without sophisticated investigational facilities such as Computed Tomogram (CT) scan or Polymerase Chain Reaction (PCR).

Case report

In August 2006, an 18 year old girl was admitted to our unit with a 12 year history of recurrent multiple joint and muscle pains, fevers and sweats. There were radicular pains felt down both arms. She was so weak that she could not even button her dress and had eventually dropped out of school 8 years earlier-she could not write or sit in class. After diagnosis, it was discovered that her family rears goats and the patient had been cleaning up animal excreta from

*Correspondence author:
Dr. Peterson Kyebambe
Department of Internal Medicine
Kabale Regional Hospital
P.O Box 7
Kabale, Uganda
Telephone: +256 772 448771
Email: kyebsnteve@yahoo.com
The yard with her bare hands for years. The animals were not immunized against brucellosis.

There was no history of consuming raw dairy products or underroasted/undercooked meat. Examination revealed a sick-looking, wasted, pale and debilitated teenager. She had marked wasting and weakness of the upper limbs with attendant inability to use her hands normally (inset A). There was marked atrophy of the hypothenar and thenar eminences of both hands with resulting difficulty in abducting or adducting the fingers (inset A1), with hypotonia and diminished reflexes in both upper limbs. In the lower limbs there was reduced muscle power but increased tone and reflexes with an extensor plantar response. She had a sensory gait and sensory level at C8 (cervical dermatome 8). The mentation and cranial nerves were intact. Other body systems were unremarkable except for generalised bone/joint tenderness.

A clinical impression of chronic cervical cord and nerve root compression of uncertain cause was made. Cervical antero-posterior, lateral and oblique view x-rays were taken revealing anterior ankylosis and narrowing between C2 and C3 plus reduced intervertebral spaces at C4/5, C5/6, C6/7 and C7/T1 indicating multiple prolapsed intervertebral discs and myelopathy at those levels (inset C). The foramina and chest x-ray were normal. A clinical-radiological diagnosis of cervical spondylitic myelo-radiculopathy was made. Advanced tests such as CT scan could not be done as they are not available in our locality (nearest CT is 400 km away).

The Hb = 10.8 grams per dl, Erythrocyte Sedimentation Rate (ESR) = 94 mm after one hour (normal = 0-20 mm, Westergren). The total leukocyte count was 3600 cells per ml total (normal is 4000-11,000) with a lymphocytosis of 63.3% (normal is 20-40%). The brucella Serum Agglutination Test (SAT) done (Cypress Diagnostics, Belgium) was significantly reactive with a titre of 1:320 after 72 hours of incubation (significant titre = 1:160 or more). There were no facilities for brucella culture or PCR. We could not do a lumbar puncture to obtain cerebrospinal fluid (CSF) for fear of aggravating the cord compression yet we do not have neurosurgical capacity. The serological tests for HIV (Determine-Abbott, Japan and Statpak-Chembio, USA) were both negative. The serological tests for tuberculosis (‘Hexagon TB’-Human, Germany), syphilis (RPR, TPHA-Abbott, Japan) and Systemic Lupus (Anti-Nuclear Antibody-Human, Germany) were all negative.

Figure 1: cervical spondylitic myeloradiculopathy due to chronic brucellosis in a teenage Ugandan female

649 x 589mm (72 x 72 DPI)
**Results**

Treatment was started with 3 drugs: intramuscular (IM) streptomycin 1 gram OD for 2 weeks together with oral doxycycline 200 mg OD and oral ofloxacin 200 mg BD for a total of 20 weeks. Streptomycin was stopped after the first 2 weeks\(^1\,\text{,}\,4\,\text{,}\,16\) and replaced by oral rifampicin 600 mg OD so as to maintain a minimum of three drugs\(^1\,\text{,}\,16\,\text{,}\,17\). Therapy was continued until irrevocable evidence of healing had been noted and the serology had turned negative—this occurred after 20 weeks (inset B). The general body, thenar and hypothenar eminences regained normal size and function (inset B1).

We have followed this patient post-treatment for over 36 months now and she has continued to do well. The family has been counselled about prevention of brucellosis.

**Discussion**

**Manifestations of neurobrucellosis**

Neurobrucellosis occurs in 3-7% of all patients with brucellosis\(^1\,\text{,}\,3\,\text{,}\,4\,\text{,}\,14\,\text{,}\,21\). The commonest manifestations are meningitis and meningoencephalitis followed by myelitis, craniopathies, peripheral neuropathy, radiculopathy, cerebellar ataxia, meningovascular complications (including mycotic aneurysms, ischaemic strokes and subarachnoid hemorrhage). Rarer manifestations include isolated intracranial hypertension, Guillain-Barre syndrome, brain abscesses, diabetes insipidus, cerebral venous thrombosis, subdural hemorrhage and psychiatric syndromes. CSF examination shows elevated protein, low glucose and a mononuclear pleocytosis. The SAT is frequently positive but brucella culture in CSF is only positive in 20% of cases\(^1\). The case we are documenting was unusual in that symptoms lasted over 12 years without the diagnosis being made and the clinical picture resembled an incurable disease like ALS. In the medical literature, there are only two African case reports of neurobrucellosis, one of which was also from our unit\(^22\,\text{,}\,23\). Despite brucellosis being an endemic infection in Africa, many healthcare providers are not conversant with it. We aim to alert health personnel in Africa and other areas, about the protean nature of brucellosis and its ability to cause chronic disease including crippling neurological manifestations.

Tuberculosis (TB) is an important differential in spondylitic brucellosis and it may be difficult to differentiate the two clinically in a resourcelimited setting. However, evidence from some workers (including ourselves) indicates that this can be possible on plain radiographs—TB tending to cause early erosions of the anterior aspect of the vertebrae with consequent bone destruction, vertebral collapse, wedging and gibbus formation unlike brucellosis which usually does not behave likewise\(^24\,\text{,}\,25\,\text{,}\,26\,\text{,}\,27\).

**Treatment of neurobrucellosis (including myelopathy)**

It is recommended to use at least 3 classes of drugs at any one time to prevent development of resistance and relapse\(^1\,\text{,}\,16\,\text{,}\,17\,\text{,}\,20\). In neurobrucellosis at least 2 of the drugs should be able to cross the blood-brain barrier. Drugs that can do so include third generation cephalosporins (e.g. ceftriaxone, cefixime), tetracyclines (usually doxycycline), rifamycins (usually rifampicin) and cotrimoxazole\(^1\,\text{,}\,16\). Caution has to be taken to exclude tuberculosis before using rifamycins because of the danger of development of resistance to rifampicin by TB bacteria if its used without other anti-tuberculous drugs in a patient with active TB\(^1\). Our therapy was successful because it continued until all signs and laboratory evidence (SAT) had cleared. Using serology alone as an indicator of successful treatment may be misleading as it can remain positive for months even after the infection has been eliminated from the patient. We followed the experiences of other clinicians in the medical literature whose subjects cured/improved after treatment for longer than the traditionally recommended 6-8 weeks\(^1\,\text{,}\,17\,\text{,}\,18\,\text{,}\,19\). At 6 weeks of therapy our case had made only a little improvement. Our findings agree with those of other authors whose patients cured/improved after these durations: Solera (45-535 days), Bodur (5 months) and Gul (2-15 months)\(^1\,\text{,}\,17\,\text{,}\,18\,\text{,}\,19\).

Serious side/toxic effects of the drugs we used include: allergy, hepatitis (rifampicin), vomiting, benign intracranial hypertension (doxycycline), psychosis (ofloxacin). Our patient was monitored monthly clinically, no significant side/toxic effect was reported or noted.

**Learning points**

1. Brucellosis is a common and often missed diagnosis in Africa.
2. Diagnosis and cure of complicated brucellosis is possible even in units without sophisticated facilities.
3. In complicated brucellosis, treatment should continue until all the clinical symptoms and signs completely resolve.

4. The people, the governments and many health workers are not aware of the presence of brucellosis and its very diverse and often deleterious manifestations. Awareness and action need to be promoted to diagnose, manage and prevent this curable but debilitating/lethal zoonosis.

References

